$ATNM  Astellas in 2013 signed collaborative Research deal with Ambrx  for antibody conjugate Platform $15 million upfront +$285 million milestones PYM: similar to Actinium's Antibody Radio-Conjugate program potential partnership. $JNJ $BMY $MRK $NVS $ABBV $PFE $SNY $LLY $VX